1. Home
  2. CAPR vs ZKH Comparison

CAPR vs ZKH Comparison

Compare CAPR & ZKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • ZKH
  • Stock Information
  • Founded
  • CAPR 2005
  • ZKH 1998
  • Country
  • CAPR United States
  • ZKH China
  • Employees
  • CAPR N/A
  • ZKH N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • ZKH
  • Sector
  • CAPR Health Care
  • ZKH
  • Exchange
  • CAPR Nasdaq
  • ZKH Nasdaq
  • Market Cap
  • CAPR 622.9M
  • ZKH 578.4M
  • IPO Year
  • CAPR N/A
  • ZKH 2023
  • Fundamental
  • Price
  • CAPR $12.79
  • ZKH $3.73
  • Analyst Decision
  • CAPR Strong Buy
  • ZKH Buy
  • Analyst Count
  • CAPR 7
  • ZKH 1
  • Target Price
  • CAPR $39.29
  • ZKH $4.00
  • AVG Volume (30 Days)
  • CAPR 1.5M
  • ZKH 52.2K
  • Earning Date
  • CAPR 03-19-2025
  • ZKH 03-18-2025
  • Dividend Yield
  • CAPR N/A
  • ZKH N/A
  • EPS Growth
  • CAPR N/A
  • ZKH N/A
  • EPS
  • CAPR N/A
  • ZKH N/A
  • Revenue
  • CAPR $23,228,045.00
  • ZKH $1,259,541,805.00
  • Revenue This Year
  • CAPR N/A
  • ZKH $0.49
  • Revenue Next Year
  • CAPR $74.85
  • ZKH $12.88
  • P/E Ratio
  • CAPR N/A
  • ZKH N/A
  • Revenue Growth
  • CAPR 65.33
  • ZKH 3.49
  • 52 Week Low
  • CAPR $3.52
  • ZKH $2.62
  • 52 Week High
  • CAPR $23.40
  • ZKH $20.07
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 42.76
  • ZKH 59.85
  • Support Level
  • CAPR $11.75
  • ZKH $3.50
  • Resistance Level
  • CAPR $16.17
  • ZKH $3.75
  • Average True Range (ATR)
  • CAPR 1.51
  • ZKH 0.22
  • MACD
  • CAPR -0.18
  • ZKH 0.02
  • Stochastic Oscillator
  • CAPR 22.96
  • ZKH 96.43

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

About ZKH ZKH Group Limited each representing thirty-five (35)

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

Share on Social Networks: